 | • レポートコード：MRC2303G146 • 出版社/出版日：Mordor Intelligence / 2023年2月 • レポート形態：英文、PDF、116ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：バイオ |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の市場調査書によると、世界の三次元細胞培養市場規模が、予測期間中（2022年-2027年）CAGR 12.5％で増加すると推測されています。本書では、三次元細胞培養の世界市場について広く調査・分析を行い、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（足場型三次元細胞培養、足場無し型三次元細胞培養、マイクロチップ、3Dバイオリアクター）分析、用途別（創薬、組織工学、臨床応用、その他）分析、エンドユーザー別（研究所・機関、バイオテクノロジー・製薬企業、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来動向などの項目について記載しています。並びに、本書に記載されている企業情報には、BiomimX SRL、CN Bio Innovations、Corning Incorporated、Hurel Corporation、InSphero AG、Lonza AG、Merck KGaA、MIMETAS BV、Nortis Inc.、Thermo Fisher Scientific、Sartorius AG、Promocell GmbHなどが含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の三次元細胞培養市場規模：製品別 - 足場型三次元細胞培養の市場規模 - 足場無し型三次元細胞培養の市場規模 - マイクロチップの市場規模 - 3Dバイオリアクターの市場規模 ・世界の三次元細胞培養市場規模：用途別 - 創薬における市場規模 - 組織工学における市場規模 - 臨床応用における市場規模 - その他用途における市場規模 ・世界の三次元細胞培養市場規模：エンドユーザー別 - 研究所・機関における市場規模 - バイオテクノロジー・製薬企業における市場規模 - その他エンドユーザーにおける市場規模 ・世界の三次元細胞培養市場規模：地域別 - 北米の三次元細胞培養市場規模 アメリカの三次元細胞培養市場規模 カナダの三次元細胞培養市場規模 メキシコの三次元細胞培養市場規模 … - ヨーロッパの三次元細胞培養市場規模 ドイツの三次元細胞培養市場規模 イギリスの三次元細胞培養市場規模 フランスの三次元細胞培養市場規模 … - アジア太平洋の三次元細胞培養市場規模 中国の三次元細胞培養市場規模 日本の三次元細胞培養市場規模 インドの三次元細胞培養市場規模 … - 南米/中東の三次元細胞培養市場規模 ブラジルの三次元細胞培養市場規模 アルゼンチンの三次元細胞培養市場規模 サウジアラビアの三次元細胞培養市場規模 ・競争状況 ・市場機会・将来動向 |
The 3D cell culture market is expected to register a CAGR of 12.5% during the forecast period, 2022-2027.
The COVID-19 pandemic is expected to have a significant impact on the market. Researchers working on COVID-19 with relevant matrices for 3D cell culture and suitable for air-liquid interface culture need to investigate in vitro the mechanisms of the systemic consequences of cell cultures and to test potential therapies in a physiological microenvironment. This is the primary reason why 3D cell cultures are used in COVID-19 research. According to an article appearing in Frontiers Online in March 2021 titled, 3D Tissue Models as an Effective Tool for Studying Viruses and Vaccine Development, there are benefits of using 3D tissue culture techniques over 2D tissue culture when studying viral infections and the implications with regards to studying COVID-19. The study also found that techniques like organoids and spheroid cultures have been shown to replicate systems of viral infection more accurately than 2D cultures and to produce morphology and biochemical behaviors required to allow for viral infection in cases where 2D cultures do not.
The 3D cell culture market is witnessing stable growth due to factors like the use of 3D cell culture models as alternative tools for in vivo testing, the development of large-scale automated cell culture systems, and the rising need for organ transplantation. The 3D cell culture and co-culture models have huge benefits since they not only enable drug safety and efficacy assessment in a more in vivo–like context than traditional 2D cell cultures, but they can eliminate the species differences that pose limitations in the interpretation of the preclinical outcomes, by allowing drug testing directly in human systems. Additionally, with the increase in demand for organ transplantation, there is likely to be a demand for 3D cell cultures as there is a need to recapitulate complex aspects of human physiology, pathology, and drug responses in vitro. According to the organdonor.gov website of the United States Health Resources and Services Administration, in October 2021, 107,103 patients were on the national organ transplant waiting list in the year 2020. Data from the website also states that each year, 39,000 organ transplants are conducted in the United States. Thus, the increase in organ transplants is increasing the demand for research models where 3D cell cultures are used. This is expected to boost the market growth.
3D Cell Culture Market Trends
The Microchips Segment under Product is Expected to see Significant Growth Rate Over the Forecast Period
Microchips are also called organ-on-a-chip or microsystems. Microchips can integrate microfluidic technologies with cells that are cultured within the microfabricated 3D devices, using various techniques from the microchip industry. For instance, the study published in the Analytical Methods in June 2019, titled Integrating 3D cell culture of PC12 cells with microchip-based electrochemical detection, identified that microchip was able to separate and detect dopamine and norepinephrine release. Thus, microchips fabricated with 3D cell culture devices help in the real-time analysis of neurotransmitters boost the segment over the forecast period.
2-dimensional (2D) culture models and animal models have been used for mechanism research and drug development. However, 2D models and animal models cannot mimic the physiology of human tissue in terms of the number of cell types and properties. Thus, conventional models cannot precisely reflect humans and have not been able to accurately predict in vivo responses related to drug treatment. In this regard, many industries have been looking for and developing a new platform to replace animal models or flask cell-culture models, and recently, organs-on-a-chip (OoCs) emerged as an alternative candidate for cell experiments and drug screening.
The main advantage of these chips is that they can be manufactured at a low cost. They allow for testing a wide range of concentrations in the dosage of medicine. This advantage is expected to drive the demand for microchips, primarily to considerably accelerate scientific research. In recent years, there have been innovative uses of organ chip technology for the drug discovery process. For example, in March 2019, the private space exploration company SpaceX announced that it plans to soon launch a Dragon cargo capsule that will contain four microchips embedded with living human cells designed to model various aspects of human physiology. This is expected to speed up analysis and glean insights on human physiology that can be used later for drug development.
As a result, due to the aforementioned advantages and research in microchips, 3D cell culture technologies are expected to drive the market’s growth.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominates the overall 3D cell culture market, with the United States being the major contributor to the market. The United States is focusing on R&D and has been making significant investments in research on 3D cell culture for the past few years. This has resulted in technological advancements in the country. Many American applicants feature among the main patent applicants for the 3D cell culture domain. American applicants tend to develop their technologies in the United States, as well as in Asia.
There have also been huge investments in the bioengineering sector in the United States over the past few years. Bioengineeringinvolves 3D cell culture research too. According to the National Institute of Health, in 2020, the total investment in various bio engineering technologies amounted to USD 5,646, an increase from USD 5,091 in 2019. These factors have augmented the US 3D cell culture market.
Moreover, there is a need to mimic intricate elements of human physiology, pathology, and medication reactions in vitro. There is expected to be a demand for 3D cell cultures as the demand for organ transplantation grows in the region. According to the Canadian Institute for Health Information, in 2021, a total of 3,014 transplant procedures (all organs) were performed in Canada (including Quebec), an increase of 42% since 2010. Thus, all the aforementioned factors are expected to boost the market in the region over the forecast period.
3D Cell Culture Market Competitor Analysis
The 3D cell culture market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. The presence of major market players, such as Corning Incorporated, Lonza AG, Merck KGaA, and Thermo Fisher Scientific, is increasing the overall competitive rivalry in the market.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Use of 3D Cell Culture Models as Alternative Tools for In Vivo Testing
4.2.2 Development of Automated Large-scale Cell Culture Systems
4.2.3 Rising Need for Organ Transplantation
4.3 Market Restraints
4.3.1 Lack of Experienced and Skilled Professionals
4.3.2 Budget Restriction for Small- and Medium-sized Laboratories
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Product
5.1.1 Scaffold-based 3D Cell Cultures
5.1.1.1 Micropatterned Surface Microplates
5.1.1.2 Hydrogels
5.1.1.3 Other Products
5.1.2 Scaffold-free 3D Cell Cultures
5.1.2.1 Hanging drop microplates
5.1.2.2 Microfluidic 3D cell culture
5.1.2.3 Other Products
5.1.3 Microchips
5.1.4 3D Bioreactors
5.2 By Application
5.2.1 Drug Discovery
5.2.2 Tissue Engineering
5.2.3 Clinical Applications
5.2.4 Other Applications
5.3 By End User
5.3.1 Research Laboratories and Institutes
5.3.2 Biotechnology and Pharmaceutical Companies
5.3.3 Other End Users
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 BiomimX SRL
6.1.2 CN Bio Innovations
6.1.3 Corning Incorporated
6.1.4 Hurel Corporation
6.1.5 InSphero AG
6.1.6 Lonza AG
6.1.7 Merck KGaA
6.1.8 MIMETAS BV
6.1.9 Nortis Inc.
6.1.10 Thermo Fisher Scientific
6.1.11 Sartorius AG
6.1.12 Promocell GmbH
7 MARKET OPPORTUNITIES AND FUTURE TRENDS